Keldsen N, Dalmark M
Department of Oncology ONA, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.
Acta Oncol. 1990;29(5):589-91. doi: 10.3109/02841869009090057.
A phase II study of cisplatin and tegafur in recurrent epidermoid head and neck cancer is presented. All patients were treated with cisplatin 100 mg/m2 every 4 weeks. Twenty-nine received tegafur 750 mg/m2 days 2-28 orally and 18 patients, who were unable to take tegafur orally, were treated with tegafur 1,500 mg/m2 intravenously days 2-5. The response rate in the oral group was 28.5% and the median survival 29 weeks. The response rate in the intravenous group was 6% and the median survival was 17 weeks. We conclude that cisplatin and oral tegafur is active against head and neck cancer.
本文介绍了顺铂和替加氟用于复发性表皮样头颈部癌的II期研究。所有患者每4周接受一次100mg/m²顺铂治疗。29例患者在第2 - 28天口服750mg/m²替加氟，18例无法口服替加氟的患者在第2 - 5天接受1500mg/m²替加氟静脉治疗。口服组的缓解率为28.5%，中位生存期为29周。静脉组的缓解率为6%，中位生存期为17周。我们得出结论，顺铂和口服替加氟对头颈部癌有效。
